Drug
Losmapimod clinical trials
Also written GW856553.
- studies test it
- 27
- open now
- 0
- in phase 3
- 3
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 18
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 1
GlaxoSmithKline (20) · Fulcrum Therapeutics (6) · Cambridge University Hospitals NHS Foundation Trust (1)
Studies
Open first, then newest update. How each study uses losmapimod is read from its arms, and is right about nine times in ten.
Testing it · 27
- Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionTerminatedPhase 2Fulcrum TherapeuticsNCT04004000Written as Losmapimod
- Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)TerminatedPhase 3Fulcrum TherapeuticsNCT05397470Written as Losmapimod
- Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)TerminatedPhase 2Fulcrum TherapeuticsNCT04264442Written as Losmapimod
- Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedPhase 2Fulcrum TherapeuticsNCT04003974Written as Losmapimod oral tablet
- Losmapimod Safety and Efficacy in COVID-19TerminatedPhase 3Fulcrum TherapeuticsNCT04511819Written as Losmapimod oral tablet
- Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsCompletedPhase 1Fulcrum TherapeuticsNCT05002231Written as Losmapimod 15 mg oral tablet
- A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT ImagingCompletedPhase 2GlaxoSmithKlineNCT00633022Written as LOSMAPIMOD 7.5 MG
- Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT02299375Written as Losmapimod tablets
- Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedPhase 2GlaxoSmithKlineNCT01218126Written as losmapimod
- A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment ElevationCompletedPhase 2GlaxoSmithKlineNCT00910962Written as GW856553
- Clinical Study to Test a New Drug to Treat Major DepressionCompletedPhase 2GlaxoSmithKlineNCT00976560Written as GW856553
- A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT00642148Written as GW856553
- To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult MalesCompletedPhase 1GlaxoSmithKlineNCT00599612Written as GW856553
- A Study of GW856553X For the Treatment of DepressionTerminatedPhase 2GlaxoSmithKlineNCT00569062Written as GW856553X
- PK Study of IV Formulation of GW856553CompletedPhase 1GlaxoSmithKlineNCT01039961Written as losmapimod 1 mg
- A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)CompletedPhase 2GlaxoSmithKlineNCT02000440Written as Losmapimod
- Efficacy Study in Lumbosacral RadiculopathyCompletedPhase 2GlaxoSmithKlineNCT01110057Written as GS856553
- A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and MoxifloxacinCompletedPhase 1GlaxoSmithKlineNCT01756495Written as Losmapimod
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)CompletedPhase 3GlaxoSmithKlineNCT02145468Written as Losmapimod 7.5 mg twice daily
- Study in Neuropathic Pain Patients With Peripheral Nerve InjuryCompletedPhase 2GlaxoSmithKlineNCT00969059Written as GW856553
Codes
What other systems call losmapimod · ClinicalTrials.gg INT005494
- UNII (FDA) F2DQF16BXELOSMAPIMODConfirmed FDA, Wikidata
- Wikidata Q6683687losmapimodConfirmed FDA, Wikidata
- NCI Thesaurus C96532LosmapimodOne source FDA
- DrugBank DB12270One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F2DQF16BXE | LOSMAPIMOD | Confirmed FDA, Wikidata |
| Wikidata | Q6683687 | losmapimod | Confirmed FDA, Wikidata |
| NCI Thesaurus | C96532 | Losmapimod | One source FDA |
| DrugBank | DB12270 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.